Keyword: Allergan

Allergan plans to double its investment in consumer advertising, grow its sales force by 20%, and launch one to two new aesthetic products every year.

Merck halves Keytruda's price in China; Takeda eyes selling Shire's Xiidra and Natpara; another ex-GSK scientist pleads guilty to trade secret theft.

Allergan already has a laundry list of celebrities backing its Alzheimer’s awareness push, but that didn’t stop it from adding one more this week.

Allergan hopes its products can be better leveraged among consumers through some 3,000 practitioners it plans to train at the center each year.

Teva’s Medis unit has attracted attention from other industry players and private equity firms, according to Bloomberg.

More turnover is coming to Allergan’s board—and this time, it’s the man who arguably built the company.

Evolus, which had its Botox rival sidelined by the FDA in May, believes it has its manufacturing figured out and says it is back on track.

Allergan aims to sell its women’s health unit, but Esmya's FDA rejection will take a big bite out of its price.

As Allergan enters a key phase for its late-stage products, it’s bringing in a veteran exec for backup.

Alllergan is suing Pfizer, saying it needs to indemnify it for claims tied to opioid drug Kadian.